US Bancorp’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $430K | Sell |
7,886
-2,617
| -25% | -$138K | ﹤0.01% | 1677 |
|
|
2026
Q1 | $500K | Buy |
10,503
+4,772
| +83% | +$252K | ﹤0.01% | 1509 |
|
|
2025
Q4 | $301K | Sell |
5,731
-46
| -0.8% | -$2.75K | ﹤0.01% | 1823 |
|
|
2025
Q3 | $374K | Buy |
5,777
+249
| +5% | +$14.3K | ﹤0.01% | 1674 |
|
|
2025
Q2 | $269K | Buy |
5,528
+2,465
| +80% | +$95.4K | ﹤0.01% | 1863 |
|
|
2025
Q1 | $104K | Buy |
3,063
+1,854
| +153% | +$78.6K | ﹤0.01% | 2375 |
|
|
2024
Q4 | $47.6K | Sell |
1,209
-1,380
| -53% | -$65.2K | ﹤0.01% | 2764 |
|
|
2024
Q3 | $122K | Sell |
2,589
-3,228
| -55% | -$164K | ﹤0.01% | 2299 |
|
|
2024
Q2 | $314K | Sell |
5,817
-24
| -0.4% | -$1.39K | ﹤0.01% | 1764 |
|
|
2024
Q1 | $398K | Sell |
5,841
-8
| -0.1% | -$573 | ﹤0.01% | 1633 |
|
|
2023
Q4 | $366K | Sell |
5,849
-494
| -8% | -$27.3K | ﹤0.01% | 1681 |
|
|
2023
Q3 | $288K | Sell |
6,343
-452
| -7% | -$23.3K | ﹤0.01% | 1655 |
|
|
2023
Q2 | $381K | Sell |
6,795
-755
| -10% | -$42.8K | ﹤0.01% | 1540 |
|
|
2023
Q1 | $341K | Buy |
7,550
+659
| +10% | +$32K | ﹤0.01% | 1610 |
|
|
2022
Q4 | $280K | Sell |
6,891
-6,425
| -48% | -$341K | ﹤0.01% | 1681 |
|
|
2022
Q3 | $870K | Buy |
13,316
+4,549
| +52% | +$330K | ﹤0.01% | 1120 |
|
|
2022
Q2 | $533K | Sell |
8,767
-759
| -8% | -$44.6K | ﹤0.01% | 1407 |
|
|
2022
Q1 | $598K | Buy |
9,526
+866
| +10% | +$54.4K | ﹤0.01% | 1451 |
|
|
2021
Q4 | $657K | Buy |
8,660
+1,464
| +20% | +$128K | ﹤0.01% | 1403 |
|
|
2021
Q3 | $805K | Buy |
7,196
+1,367
| +23% | +$172K | ﹤0.01% | 1303 |
|
|
2021
Q2 | $944K | Buy |
5,829
+599
| +11% | +$72.8K | ﹤0.01% | 1229 |
|
|
2021
Q1 | $638K | Buy |
5,230
+3,973
| +316% | +$600K | ﹤0.01% | 1372 |
|
|
2020
Q4 | $193K | Buy |
1,257
+62
| +5% | +$7.33K | ﹤0.01% | 1892 |
|
|
2020
Q3 | $100K | Sell |
1,195
-1,100
| -48% | -$97.6K | ﹤0.01% | 2086 |
|
|
2020
Q2 | $169K | Hold |
2,295
| – | – | ﹤0.01% | 1848 |
|
|
2020
Q1 | $97K | Buy |
2,295
+125
| +6% | +$6.45K | ﹤0.01% | 2036 |
|
|
2019
Q4 | $132K | Buy |
2,170
+2,000
| +1,176% | +$109K | ﹤0.01% | 2027 |
|
|
2019
Q3 | $7K | Sell |
170
-451
| -73% | -$21.6K | ﹤0.01% | 3145 |
|
|
2019
Q2 | $29K | Buy |
621
+526
| +554% | +$21K | ﹤0.01% | 2747 |
|
|
2019
Q1 | $3K | Hold |
95
| – | – | ﹤0.01% | 3338 |
|
|
2018
Q4 | $3K | Hold |
95
| – | – | ﹤0.01% | 3312 |
|
|
2018
Q3 | $4K | Buy |
+95
| New | +$4.97K | ﹤0.01% | 3360 |
|
|
2017
Q2 | – | Sell |
-39
| Closed | -$1K | – | 3543 |
|
|
2017
Q1 | $1K | Buy |
+39
| New | +$766 | ﹤0.01% | 3453 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
US Bancorp's CRSP Position: Q2 2026 in Review
US Bancorp reduced its CRISPR Therapeutics (CRSP) stake by 25% in Q2 2026, selling an estimated $138K and leaving 7,886 shares worth $430K. The position accounts for ﹤0.01% of the portfolio, ranked #1677.
US Bancorp first reported a position in CRSP in Q1 2017 and has held it in 33 quarters since. The position peaked at $944K in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- US Bancorp held 7,886 shares of CRISPR Therapeutics worth $430K as of Q2 2026.
- US Bancorp sold 2,617 CRISPR Therapeutics shares in Q2 2026, an estimated $138K.
- CRISPR Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1677 holding.
- US Bancorp first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 33 quarters since.
- US Bancorp's CRISPR Therapeutics position peaked at $944K in Q2 2021.
- 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.